Disseminated intravascular coagulation: What's new?

被引:75
作者
Levi, M [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc & Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.ccc.2005.02.001
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Disseminated intravascular coagulation (DIC) is a syndrome characterized by a systemic activation of coagulation leading to the intravascular deposition of fibrin in the (micro) vasculature and the simultaneous consumption of coagulation factors and platelets. The occurrence of microvascular thrombosis as a consequence of DIC is underscored by pathological, experimental and clinical findings, demonstrating a link between DIC and organ dysfunction. Pathogenetic pathways that play a role in the development of DIC include tissue factor-dependent activation of coagulation, defective physiological anticoagulant pathways (such as the antithrombin system and the protein C system), and impaired fibrinolysis, caused by elevated levels of plasminogen activator inhibitor type 1. Novel therapeutic strategies are based on current insights into the pathogenesis of DIC, and include anticoagulant strategies (eg, directed at tissue factor) and strategies to restore physiological anticoagulant pathways (such as activated protein C concentrate).
引用
收藏
页码:449 / +
页数:20
相关论文
共 77 条
[1]   Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].
Abraham, E ;
Reinhart, K ;
Svoboda, P ;
Seibert, A ;
Olthoff, D ;
Dal Nogare, A ;
Postier, R ;
Hempelmann, G ;
Butler, T ;
Martin, E ;
Zwingelstein, C ;
Percell, S ;
Shu, V ;
Leighton, A ;
Creasey, AA .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089
[2]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]   Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment [J].
Aird, WC ;
Edelberg, JM ;
WeilerGuettler, H ;
Simmons, WW ;
Smith, TW ;
Rosenberg, RD .
JOURNAL OF CELL BIOLOGY, 1997, 138 (05) :1117-1124
[4]   Vascular bed-specific hemostasis: Role of endothelium in pathogenesis [J].
Aird, WC .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S28-S34
[5]   Time course of platelet counts in critically ill patients [J].
Akca, S ;
Haji-Michael, P ;
de Mendonça, A ;
Suter, P ;
Levi, M ;
Vincent, JL .
CRITICAL CARE MEDICINE, 2002, 30 (04) :753-756
[6]  
Alving BM, 1998, HEMATOLOGY, P320
[7]   A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation [J].
Aoki, N ;
Matsuda, T ;
Saito, H ;
Takatsuki, K ;
Okajima, K ;
Takahashi, H ;
Takamatsu, J ;
Asakura, H ;
Ogawa, N .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 75 (05) :540-547
[8]  
Baglin T, 1996, BMJ-BRIT MED J, V312, P683
[9]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[10]   Disseminated intravascular coagulation in acute leukemia [J].
Barbui, T ;
Falanga, A .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (06) :593-604